CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity. Oya S, Ozawa H, Nakamura T, Mori A, et al. Int J Hematol 2024;120:194-202.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Oya S, Ozawa H, Nakamura T, Mori A, et al. CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity. Int J Hematol 2024;120:194-202.
PMID: 38853211